Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL6413526 | 0.95 | MEN1 (0.35) | MEN1POLBCASP6KMT2AP2RY6 | |
| SCHEMBL1491181 | 0.67 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL5494922 | 0.67 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL22115886 | 0.67 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL3235007 | 0.67 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL1661412 | 0.67 | BRD4 (0.34) | MEN1KMT2A | |
| SCHEMBL3342528 | 0.67 | KDM4E (0.37) | MEN1KMT2A | |
| SCHEMBL7383136 | 0.67 | HTR2C (0.31) | MEN1KMT2A | |
| SCHEMBL17923825 | 0.66 | LMNA (0.37) | MEN1KMT2AP2RY6 | |
| Ammonia Solution, Strong SCHEMBL27779538 | 0.66 | BRD4 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118704272-A | Flame-retardant archival product paper and preparation method thereof | 河北墨达纸业有限公司 | 2024-09-27 | — | — | CN | claimed |
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | claimed |
| EP-0103797-B1 | SUBSTITUTED BENZOXAZINE DERIVATIVES | BAYER AG (DE) | 1986-11-26 | — | — | EP | claimed |
| JP-61140571-A | — | — | None | — | — | JP | disclosed |
| CN-118704272-A | Flame-retardant archival product paper and preparation method thereof | 河北墨达纸业有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-7799913-B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| US-6919334-B2 | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine | WYETH (US) | 2005-07-19 | — | — | US | disclosed |
| CN-1620440-A | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMA INC (US) | 2005-05-25 | — | — | CN | disclosed |
| US-5118323-A | Hair dyes | CLAIROL, INC. | 1992-06-02 | — | — | US | disclosed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| US-5055110-A | Hair dyes | CLAIROL INCORPORATED (US) | 1991-10-08 | — | — | US | disclosed |
| US-5030643-A | Antiallergens, antiinflammatory agents | ICI AMERICAS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| WO-1991007394-A1 | BENZOXAZINE DYES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-05-30 | — | — | WO | disclosed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| JP-S61140571-A | NITROBENZOXAZINE DERIVATIVE, AND PREPARATION THEREOF | SUMITOMO CHEM CO LTD | 1986-06-27 | — | — | JP | disclosed |
| US-4537888-A | Substituted benzoxazine derivatives and fungicidal use | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | MEN1 2402/4885POLB 2317/4885CASP6 4633/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | MEN1 2402/4885POLB 2317/4885CASP6 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.